02. June 2016

SN38 (7-ethyl-10-hydroxycamptothecin) is a highly potent anti-cancer compound. However, it is poorly soluble in pharmaceutically acceptable excipients, thus the direct formulation and delivery is restricted. The current study focused on lipid-based formulation design to enable oral delivery of SN38 at high doses and at therapeutic levels. The pH dependent ionisation property of SN38 was utilized to form a molecular complex with the cationic surfactant, oleylamine and this increased (>...